20 years of HPV research with 4 and 9 valent HPV vaccine: long term follow-up
Tuesday, October 10, 2017
•
SS 06
•
9:30 AM
>
11:00 AM
•
20 years of HPV research with 4 and 9 valent HPV vaccine: long term follow-up
•
G 102-103
•
SS 06-01
•
QHPV and 9VHPV vaccines : 20 years of clinical research & development
See abstract
>
A.
Anna
GIULIANO
•
SS 06-02
•
Long-term effectiveness and immunogenicity of Gardasil™ in the nordic countries
See abstract
>
S.
Susanne
KJAER
•
SS 06-03
•
Effectiveness, immunogenicity, and safety of Gardasil in pre-adolescents and adolescents - 10 years follow-up
See abstract
>
O-E.
Ole-Erik
IVERSEN
•
SS 06-04
•
Long-term effectiveness of Gardasil™ among adult women in Colombia
See abstract
>
R.
Rita
DAS
•
SS 06-05
•
A long-term effectiveness, immunogenicity, and safety study of Gardasil™ (human papillomavirus [ types 6,11,16,18] recombinant vaccine) in young men V 501-020)
See abstract
>
J.
Joel
PALEFSKY
•
SS 06-06
•
Efficacy and immunogenicity of the 9-valent HPV vaccine: final analyses of a randomized, double-blind trial with up to 6 years of follow-up
See abstract
>
E.
Elmar
JOURA
•
SS 06-07
•
Design a long-term follow-up effectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccine
See abstract
>
M.
Mari
NYGÅRD
•
SS 06-08
•
V503-002-2 LTFU M&F adolescents (6 year)
>
S.
S.E.
OLSSON
•
SS 06-09
•
Comparison of immunogenicity of 2-dose and 3-dose regimens of 9-valent (9v) HPV vaccine
See abstract
>
J.
Jacob
BORNSTEIN
|